Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bipolar Disorder | 16 | 2021 | 307 | 4.650 |
Why?
|
| Alcoholism | 8 | 2021 | 1109 | 1.600 |
Why?
|
| Substance-Related Disorders | 10 | 2018 | 1242 | 1.290 |
Why?
|
| Taurine | 3 | 2012 | 51 | 1.170 |
Why?
|
| Anxiety Disorders | 6 | 2018 | 426 | 1.040 |
Why?
|
| Alcohol Deterrents | 3 | 2012 | 86 | 0.850 |
Why?
|
| gamma-Aminobutyric Acid | 3 | 2021 | 208 | 0.820 |
Why?
|
| Reward | 2 | 2021 | 201 | 0.800 |
Why?
|
| Glutamic Acid | 3 | 2021 | 332 | 0.750 |
Why?
|
| Punishment | 1 | 2021 | 25 | 0.750 |
Why?
|
| Amphetamine-Related Disorders | 5 | 2012 | 92 | 0.700 |
Why?
|
| Psychiatric Status Rating Scales | 8 | 2018 | 782 | 0.680 |
Why?
|
| Behavior, Addictive | 3 | 2012 | 317 | 0.660 |
Why?
|
| Marijuana Abuse | 1 | 2021 | 251 | 0.610 |
Why?
|
| Depression | 2 | 2016 | 943 | 0.570 |
Why?
|
| Disability Evaluation | 1 | 2018 | 298 | 0.560 |
Why?
|
| Cocaine | 7 | 2002 | 555 | 0.490 |
Why?
|
| Adult | 24 | 2021 | 21403 | 0.480 |
Why?
|
| Amphetamine | 5 | 2002 | 77 | 0.480 |
Why?
|
| Mood Disorders | 1 | 2015 | 132 | 0.460 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 5 | 2018 | 151 | 0.430 |
Why?
|
| Double-Blind Method | 6 | 2021 | 1738 | 0.420 |
Why?
|
| Mental Disorders | 2 | 2008 | 659 | 0.410 |
Why?
|
| Central Nervous System Stimulants | 6 | 2011 | 221 | 0.400 |
Why?
|
| Affect | 2 | 2018 | 218 | 0.400 |
Why?
|
| Comorbidity | 8 | 2018 | 1426 | 0.390 |
Why?
|
| Male | 33 | 2021 | 37321 | 0.390 |
Why?
|
| Piperazines | 2 | 2008 | 206 | 0.390 |
Why?
|
| Methamphetamine | 2 | 2010 | 132 | 0.390 |
Why?
|
| Nootropic Agents | 1 | 2011 | 18 | 0.380 |
Why?
|
| Behavior, Animal | 3 | 1999 | 470 | 0.380 |
Why?
|
| Antipsychotic Agents | 2 | 2008 | 247 | 0.380 |
Why?
|
| Depressive Disorder | 1 | 2015 | 621 | 0.380 |
Why?
|
| Motor Activity | 8 | 2002 | 621 | 0.370 |
Why?
|
| Gyrus Cinguli | 3 | 2021 | 113 | 0.360 |
Why?
|
| Patient Dropouts | 1 | 2011 | 98 | 0.360 |
Why?
|
| Middle Aged | 16 | 2021 | 21147 | 0.350 |
Why?
|
| Psychometrics | 3 | 2018 | 514 | 0.350 |
Why?
|
| Stereotyped Behavior | 5 | 1998 | 42 | 0.340 |
Why?
|
| Female | 22 | 2021 | 38074 | 0.320 |
Why?
|
| Hypertriglyceridemia | 1 | 2008 | 21 | 0.320 |
Why?
|
| Humans | 28 | 2021 | 68618 | 0.310 |
Why?
|
| Triglycerides | 1 | 2008 | 184 | 0.300 |
Why?
|
| Clinical Trials as Topic | 2 | 2011 | 848 | 0.300 |
Why?
|
| Quinolones | 1 | 2008 | 60 | 0.300 |
Why?
|
| Adolescent | 9 | 2021 | 8912 | 0.260 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 805 | 0.250 |
Why?
|
| Markov Chains | 2 | 2018 | 133 | 0.250 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 2 | 2021 | 27 | 0.230 |
Why?
|
| Treatment Outcome | 6 | 2018 | 7029 | 0.220 |
Why?
|
| Self Report | 2 | 2021 | 371 | 0.200 |
Why?
|
| Impulsive Behavior | 2 | 2019 | 85 | 0.190 |
Why?
|
| Dizocilpine Maleate | 2 | 2000 | 43 | 0.180 |
Why?
|
| Drug Tolerance | 3 | 1994 | 80 | 0.180 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1553 | 0.170 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2015 | 257 | 0.170 |
Why?
|
| Cigarette Smoking | 1 | 2021 | 104 | 0.170 |
Why?
|
| Young Adult | 4 | 2021 | 5717 | 0.170 |
Why?
|
| Cyclic AMP | 2 | 1999 | 223 | 0.170 |
Why?
|
| Ventral Tegmental Area | 2 | 2002 | 74 | 0.170 |
Why?
|
| Benztropine | 1 | 1999 | 2 | 0.170 |
Why?
|
| Delay Discounting | 1 | 2019 | 7 | 0.170 |
Why?
|
| Adenylyl Cyclases | 1 | 1999 | 94 | 0.170 |
Why?
|
| Nucleus Accumbens | 2 | 2000 | 417 | 0.160 |
Why?
|
| Dopamine | 2 | 1999 | 474 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2011 | 1465 | 0.160 |
Why?
|
| Research Design | 2 | 2021 | 729 | 0.160 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 1999 | 93 | 0.160 |
Why?
|
| Membrane Transport Proteins | 1 | 1999 | 81 | 0.160 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2002 | 152 | 0.160 |
Why?
|
| Cognition Disorders | 2 | 2012 | 342 | 0.160 |
Why?
|
| Stress, Physiological | 2 | 1998 | 215 | 0.160 |
Why?
|
| Cognition | 2 | 2011 | 513 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2021 | 1342 | 0.140 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2002 | 2083 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 1 | 1999 | 290 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2018 | 206 | 0.140 |
Why?
|
| Cross-Sectional Studies | 4 | 2018 | 2279 | 0.140 |
Why?
|
| Cholera Toxin | 1 | 1996 | 30 | 0.140 |
Why?
|
| Membrane Glycoproteins | 1 | 1999 | 370 | 0.140 |
Why?
|
| Surveys and Questionnaires | 4 | 2021 | 2800 | 0.140 |
Why?
|
| Haloperidol | 1 | 1996 | 95 | 0.140 |
Why?
|
| Tegmentum Mesencephali | 1 | 1996 | 52 | 0.130 |
Why?
|
| Severity of Illness Index | 4 | 2016 | 1851 | 0.130 |
Why?
|
| Carrier Proteins | 1 | 1999 | 597 | 0.130 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2016 | 41 | 0.130 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1999 | 435 | 0.130 |
Why?
|
| Resilience, Psychological | 1 | 2016 | 43 | 0.130 |
Why?
|
| Veterans Health | 1 | 2016 | 62 | 0.130 |
Why?
|
| Prevalence | 3 | 2015 | 1619 | 0.120 |
Why?
|
| Mice, Inbred DBA | 4 | 1995 | 120 | 0.120 |
Why?
|
| Cues | 4 | 2012 | 654 | 0.120 |
Why?
|
| Species Specificity | 4 | 1995 | 303 | 0.120 |
Why?
|
| Rats | 9 | 2002 | 5300 | 0.110 |
Why?
|
| Neuroprotective Agents | 1 | 1996 | 317 | 0.110 |
Why?
|
| Dietary Supplements | 1 | 2016 | 332 | 0.110 |
Why?
|
| Photic Stimulation | 2 | 2012 | 229 | 0.110 |
Why?
|
| Models, Psychological | 2 | 2011 | 180 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 2223 | 0.100 |
Why?
|
| Affective Symptoms | 1 | 2012 | 50 | 0.100 |
Why?
|
| Suicide, Attempted | 2 | 2009 | 72 | 0.100 |
Why?
|
| Disease Progression | 1 | 2015 | 1038 | 0.100 |
Why?
|
| Adrenergic Agents | 1 | 2011 | 14 | 0.100 |
Why?
|
| Animals | 13 | 2002 | 20881 | 0.100 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2011 | 20 | 0.100 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2011 | 58 | 0.090 |
Why?
|
| Benzhydryl Compounds | 1 | 2011 | 62 | 0.090 |
Why?
|
| Neurotransmitter Agents | 1 | 2011 | 102 | 0.090 |
Why?
|
| Nicotinic Agonists | 1 | 2011 | 111 | 0.090 |
Why?
|
| Association Learning | 1 | 2010 | 36 | 0.090 |
Why?
|
| Galvanic Skin Response | 1 | 2010 | 67 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 1999 | 1745 | 0.090 |
Why?
|
| Risk-Taking | 1 | 2011 | 210 | 0.090 |
Why?
|
| Microdialysis | 3 | 1999 | 147 | 0.080 |
Why?
|
| Logistic Models | 2 | 2010 | 1420 | 0.080 |
Why?
|
| Microinjections | 2 | 1999 | 130 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2011 | 402 | 0.080 |
Why?
|
| Periodicity | 1 | 2008 | 43 | 0.080 |
Why?
|
| Veterans | 1 | 2016 | 904 | 0.080 |
Why?
|
| Extinction, Psychological | 1 | 2010 | 240 | 0.080 |
Why?
|
| Aripiprazole | 1 | 2008 | 43 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2007 | 951 | 0.080 |
Why?
|
| Coercion | 1 | 2008 | 11 | 0.080 |
Why?
|
| Mandatory Programs | 1 | 2008 | 8 | 0.080 |
Why?
|
| Rural Population | 1 | 2011 | 398 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 4 | 1995 | 2791 | 0.080 |
Why?
|
| Motivation | 1 | 2012 | 561 | 0.080 |
Why?
|
| Heart Rate | 1 | 2010 | 568 | 0.070 |
Why?
|
| Weight Gain | 1 | 2008 | 135 | 0.070 |
Why?
|
| Behavior Therapy | 1 | 2010 | 297 | 0.070 |
Why?
|
| Drug-Seeking Behavior | 1 | 2010 | 213 | 0.070 |
Why?
|
| Psychotropic Drugs | 1 | 2007 | 83 | 0.070 |
Why?
|
| Locomotion | 3 | 1996 | 135 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1999 | 381 | 0.070 |
Why?
|
| Patient Selection | 1 | 2010 | 592 | 0.070 |
Why?
|
| Alcohol-Related Disorders | 1 | 2007 | 95 | 0.070 |
Why?
|
| Ligands | 2 | 1999 | 317 | 0.070 |
Why?
|
| Mice | 4 | 1995 | 8474 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2002 | 73 | 0.050 |
Why?
|
| Phospholipases A | 2 | 2002 | 41 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 248 | 0.050 |
Why?
|
| Anterior Thalamic Nuclei | 1 | 2000 | 4 | 0.040 |
Why?
|
| Narcotics | 1 | 2000 | 65 | 0.040 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2002 | 167 | 0.040 |
Why?
|
| Morphine | 1 | 2000 | 76 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2000 | 114 | 0.040 |
Why?
|
| Restraint, Physical | 2 | 1998 | 59 | 0.040 |
Why?
|
| Pyramidal Cells | 1 | 2000 | 79 | 0.040 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2000 | 128 | 0.040 |
Why?
|
| Drug Antagonism | 1 | 1999 | 6 | 0.040 |
Why?
|
| Neuropsychological Tests | 2 | 2012 | 517 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 1 | 1999 | 89 | 0.040 |
Why?
|
| Discrimination Learning | 1 | 1999 | 45 | 0.040 |
Why?
|
| Demography | 2 | 2011 | 279 | 0.040 |
Why?
|
| South Carolina | 2 | 2019 | 2752 | 0.040 |
Why?
|
| Personality Inventory | 2 | 2012 | 197 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2018 | 53 | 0.040 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 1999 | 82 | 0.040 |
Why?
|
| Metyrapone | 1 | 1998 | 3 | 0.040 |
Why?
|
| United States | 3 | 2018 | 7367 | 0.040 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2000 | 266 | 0.040 |
Why?
|
| Panic Disorder | 2 | 2008 | 121 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 281 | 0.030 |
Why?
|
| Quinacrine | 1 | 1996 | 10 | 0.030 |
Why?
|
| Aged | 1 | 2011 | 14862 | 0.030 |
Why?
|
| Craving | 1 | 2017 | 200 | 0.030 |
Why?
|
| Stimulation, Chemical | 1 | 1995 | 57 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1054 | 0.030 |
Why?
|
| Suicide | 1 | 2016 | 116 | 0.030 |
Why?
|
| Serotonin | 1 | 1995 | 144 | 0.030 |
Why?
|
| Norepinephrine | 1 | 1995 | 276 | 0.030 |
Why?
|
| Individuality | 1 | 2012 | 44 | 0.030 |
Why?
|
| Genotype | 1 | 1994 | 786 | 0.020 |
Why?
|
| Prefrontal Cortex | 1 | 2017 | 640 | 0.020 |
Why?
|
| Reaction Time | 1 | 2012 | 170 | 0.020 |
Why?
|
| Motor Skills | 1 | 2011 | 88 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2012 | 213 | 0.020 |
Why?
|
| Neurons | 1 | 1996 | 881 | 0.020 |
Why?
|
| Signal Transduction | 1 | 1999 | 2689 | 0.020 |
Why?
|
| Phospholipases A2 | 2 | 2002 | 32 | 0.020 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2009 | 20 | 0.020 |
Why?
|
| Marital Status | 1 | 2009 | 65 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2011 | 295 | 0.020 |
Why?
|
| Risk Factors | 2 | 2010 | 5731 | 0.020 |
Why?
|
| Age of Onset | 1 | 2009 | 188 | 0.020 |
Why?
|
| Violence | 1 | 2010 | 275 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 880 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 195 | 0.020 |
Why?
|
| Culture | 1 | 2008 | 75 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2008 | 71 | 0.020 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2008 | 88 | 0.020 |
Why?
|
| Temperance | 1 | 2007 | 41 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 4848 | 0.020 |
Why?
|
| Child Abuse | 1 | 2008 | 186 | 0.020 |
Why?
|
| Life Change Events | 1 | 2007 | 223 | 0.020 |
Why?
|
| Mental Health Services | 1 | 2008 | 199 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 1266 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 2007 | 184 | 0.020 |
Why?
|
| Naltrexone | 1 | 2007 | 195 | 0.020 |
Why?
|
| Psychotherapy | 1 | 2007 | 253 | 0.010 |
Why?
|
| Incidence | 1 | 2008 | 1603 | 0.010 |
Why?
|
| Brain | 1 | 1994 | 2176 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 931 | 0.010 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2002 | 19 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2008 | 2358 | 0.010 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2002 | 73 | 0.010 |
Why?
|
| Morphine Dependence | 1 | 2000 | 4 | 0.010 |
Why?
|
| Antisense Elements (Genetics) | 1 | 2000 | 6 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 2000 | 16 | 0.010 |
Why?
|
| Muscimol | 1 | 2000 | 26 | 0.010 |
Why?
|
| GABA Agonists | 1 | 2000 | 23 | 0.010 |
Why?
|
| Baclofen | 1 | 2000 | 24 | 0.010 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2000 | 42 | 0.010 |
Why?
|
| Receptors, AMPA | 1 | 2000 | 99 | 0.010 |
Why?
|
| Nerve Degeneration | 1 | 2000 | 134 | 0.010 |
Why?
|
| Schizophrenia | 1 | 2000 | 206 | 0.010 |
Why?
|
| Neural Pathways | 1 | 2000 | 324 | 0.010 |
Why?
|
| Corticosterone | 1 | 1998 | 51 | 0.010 |
Why?
|
| Gene Expression | 1 | 2000 | 770 | 0.010 |
Why?
|
| Child | 1 | 2008 | 6405 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2008 | 7277 | 0.010 |
Why?
|
| Caffeine | 1 | 1996 | 81 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1998 | 1040 | 0.010 |
Why?
|